Systematic use of phenotype evidence in clinical genetic testing reduces the frequency of variants of uncertain significance.

curated gene-disease relationships diagnostic yield genetic testing phenotype variant interpretation variants of uncertain significance

Journal

American journal of medical genetics. Part A
ISSN: 1552-4833
Titre abrégé: Am J Med Genet A
Pays: United States
ID NLM: 101235741

Informations de publication

Date de publication:
09 2022
Historique:
received: 19 04 2022
accepted: 23 04 2022
pubmed: 17 5 2022
medline: 17 8 2022
entrez: 16 5 2022
Statut: ppublish

Résumé

Guidelines for variant interpretation include criteria for incorporating phenotype evidence, but this evidence is inconsistently applied. Systematic approaches to using phenotype evidence are needed. We developed a method for curating disease phenotypes as highly or moderately predictive of variant pathogenicity based on the frequency of their association with disease-causing variants. To evaluate this method's accuracy, we retrospectively reviewed variants with clinical classifications that had evolved from uncertain to definitive in genes associated with curated predictive phenotypes. To demonstrate the clinical validity and utility of this approach, we compared variant classifications determined with and without predictive phenotype evidence. The curation method was accurate for 93%-98% of eligible variants. Among variants interpreted using highly predictive phenotype evidence, the percentage classified as pathogenic or likely pathogenic was 80%, compared with 46%-54% had the evidence not been used. Positive results among individuals harboring variants with highly predictive phenotype-guided interpretations would have been missed in 25%-37% of diagnostic tests and 39%-50% of carrier screens had other approaches to phenotype evidence been used. In summary, predictive phenotype evidence associated with specific curated genes can be systematically incorporated into variant interpretation to reduce uncertainty and increase the clinical utility of genetic testing.

Identifiants

pubmed: 35570716
doi: 10.1002/ajmg.a.62779
pmc: PMC9544038
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2642-2651

Informations de copyright

© 2022 Invitae. American Journal of Medical Genetics Part A published by Wiley Periodicals LLC.

Références

J Mol Diagn. 2015 Sep;17(5):533-44
pubmed: 26207792
BMC Bioinformatics. 2014 Jul 21;15:248
pubmed: 25047600
Ann Am Thorac Soc. 2016 Aug;13(8):1305-13
pubmed: 27070726
Ann Am Thorac Soc. 2014 Mar;11(3):351-9
pubmed: 24498942
Hum Mutat. 2018 Nov;39(11):1581-1592
pubmed: 30311380
Genet Med. 2018 Mar;20(3):351-359
pubmed: 29300372
Hum Mutat. 2018 Nov;39(11):1553-1568
pubmed: 30311375
Genes (Basel). 2020 Apr 23;11(4):
pubmed: 32340307
Am J Hum Genet. 2016 Jul 7;99(1):247
pubmed: 27392081
Genet Med. 2018 Nov;20(11):1334-1345
pubmed: 29493581
Genet Med. 2019 Jan;21(1):114-123
pubmed: 29895855
Am J Med Genet A. 2022 Sep;188(9):2642-2651
pubmed: 35570716
Hum Mutat. 2018 Nov;39(11):1569-1580
pubmed: 30311390
Hum Mutat. 2018 Nov;39(11):1614-1622
pubmed: 30311389
Genet Med. 2015 Dec;17(12):1012
pubmed: 26540153
Am J Hum Genet. 2018 Jul 5;103(1):58-73
pubmed: 29961570
Am J Respir Crit Care Med. 2018 Jun 15;197(12):e24-e39
pubmed: 29905515
Hum Mutat. 2019 Oct;40(10):1797-1812
pubmed: 31231902
Genet Med. 2022 Aug;24(8):1732-1742
pubmed: 35507016
Hum Mutat. 2015 Oct;36(10):915-21
pubmed: 26295439
Genet Med. 2017 Oct;19(10):1105-1117
pubmed: 28492532
G3 (Bethesda). 2015 Jul 02;5(8):1775-81
pubmed: 26139845
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868

Auteurs

Britt Johnson (B)

Invitae Corporation, San Francisco, California, USA.

Karen Ouyang (K)

Invitae Corporation, San Francisco, California, USA.

Lauren Frank (L)

Indiana University Health, Indianapolis, Indiana, USA.

Rebecca Truty (R)

Invitae Corporation, San Francisco, California, USA.

Susan Rojahn (S)

Invitae Corporation, San Francisco, California, USA.

Ana Morales (A)

Invitae Corporation, San Francisco, California, USA.

Swaroop Aradhya (S)

Invitae Corporation, San Francisco, California, USA.

Keith Nykamp (K)

Invitae Corporation, San Francisco, California, USA.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Vancomycin-associated DRESS demonstrates delay in AST abnormalities.

Ahmed Hussein, Kateri L Schoettinger, Jourdan Hydol-Smith et al.
1.00
Humans Drug Hypersensitivity Syndrome Vancomycin Female Male
Humans Immune Checkpoint Inhibitors Lung Neoplasms Prognosis Inflammation
Humans Arthroplasty, Replacement, Hip Male Female Obesity, Morbid

Classifications MeSH